R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
Delivery of molecular and cellular medicine to solid tumors1PII of original article: S0169-409X(97)00027-6. The article was originally published in Advanced Drug Delivery Reviews 26 (1997) 71–90.1
TL;DR: A paradigm of analysis and synthesis has allowed us to obtain a better understanding of physiological barriers in solid tumors, and to develop novel strategies to exploit and/or to overcome these barriers for improved cancer detection and treatment.
Journal ArticleDOI
Malignant cells facilitate lung metastasis by bringing their own soil
Dan G. Duda,Annique M M J Duyverman,Mitsutomo Kohno,Matija Snuderl,Ernst J. A. Steller,Ernst J. A. Steller,Dai Fukumura,Rakesh K. Jain +7 more
TL;DR: It is demonstrated that partial depletion of the carcinoma-associated fibroblasts, which spontaneously spread to the lung tissue along with metastatic cancer cells, significantly decreases the number of metastases and extends survival after primary tumor resection.
Journal ArticleDOI
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett,Dan G. Duda,Emmanuelle di Tomaso,Yves Boucher,Marek Ancukiewicz,Dushyant V. Sahani,Johanna Lahdenranta,Daniel C. Chung,Alan J. Fischman,Gregory Y. Lauwers,Paul C. Shellito,Brian G. Czito,Terence Z. Wong,Erik K. Paulson,Martin Poleski,Zeljko Vujaskovic,Rex C. Bentley,Helen X. Chen,Jeffrey W. Clark,Rakesh K. Jain +19 more
TL;DR: Bvacizumab with chemoradiotherapy appears safe and active and yields promising survival results in locally advanced rectal cancer.
Journal ArticleDOI
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
TL;DR: The local and systemic effects of VEGF on tumor immunity are discussed and a potentially translatable strategy to re-engineer the tumor-immune microenvironment and improve cancer immunotherapy by using lower "vascular normalizing" doses of antiangiogenic agents is proposed.
Journal ArticleDOI
Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor,Dan G. Duda,Emmanuelle di Tomaso,Marek Ancukiewicz,Scott R. Plotkin,Elizabeth R. Gerstner,April F. Eichler,Jan Drappatz,Fred H. Hochberg,Thomas Benner,David N. Louis,Kenneth S. Cohen,Houng Chea,Alexis Exarhopoulos,Jay S. Loeffler,Marsha A. Moses,Percy Ivy,A. Gregory Sorensen,Patrick Y. Wen,Rakesh K. Jain +19 more
TL;DR: Cediranib monotherapy for recurrent glioblastoma is associated with encouraging proportions of radiographic response, 6-month progression-free survival, and a steroid-sparing effect with manageable toxicity.